Listening to music reduces the overall severity of insomnia, improves sleep quality and helps to initiate sleep. The effect was comparable to prescription sleep medications, such as the Z-drugs and benzodiazepines.
A Ludwig Cancer Research study has discovered that the presence of relatively high numbers of immune cells known as monocytes in tumors is linked to better outcomes in esophageal cancer patients treated with a combination of chemotherapy and immunotherapy, or immunochemotherapy.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. If you’re looking for resources who can comment on skin cancer awareness and skin protection during the summer months, see our list of experts and reach out to [email protected] to set up interviews.
Sarcoma can be a difficult disease to detect and is often called ‘the forgotten cancer,’ that can grow in connective tissue like bones, nerves, muscles, tendons, cartilage and blood vessels of the arms and legs. It causes abdominal pain, lump, bone pain, and weight loss, and makes up approximately 1 percent of all adult cancer diagnoses. Understanding more about this disease can help people to identify it early. Learn more about Sarcoma in this blog.
Cancer cells with extra chromosomes depend on those chromosomes for tumor growth, a new Yale study reveals, and eliminating them prevents the cells from forming tumors. The findings, said the researchers, suggest that selectively targeting extra chromosomes may offer a new route for treating cancer. The study was published July 6 in the journal Science.
A single-cell study led by MD Anderson researchers and published in Cancer Cell provides a deeper understanding of the evolution of the tumor microenvironment during gastric cancer progression.
Rutgers Cancer Institute of New Jersey has treated its first patient using genetically modified T-cells that were manufactured in its own state-of-the-art Good Manufacturing Practices (GMP) facility.
Moffitt Cancer Center researchers having been investigating what may trigger treatment related symptoms in patients with gynecologic cancers. In a new study published in the journal Cancers, they evaluated the relationship between inflammatory biomarkers and self-reported treatment related symptoms among this patient population.
Low-risk branch duct intraductal papillary mucinous neoplasms (IPMN) are the most common precancerous form of mucinous pancreatic cysts and once identified require regular surveillance imaging. But consensus is still forming around how long that watchful period should last.
A blood-based four-protein panel (4MP), when combined with a lung cancer risk model (PLCOm2012), can better identify those at high risk of dying from lung cancer than the current U.S. Preventive Services Task Force (USPSTF) criteria.
Christina Glytsou, PhD, member of the Cancer Metabolism and Immunology Cancer Pharmacology Program at Rutgers Cancer Institute of New Jersey, has received an award from The V Foundation for Cancer Research, a premier cancer research charity, to support her research on mitochondrial dynamics adaptations in drug-resistant acute myeloid leukemia.
A new study led by researchers at The University of Texas MD Anderson Cancer, University of California, Irvine and Baylor College of Medicine has created the world’s largest and most comprehensive map of normal breast tissue, providing an unprecedented understanding of mammary biology that may help identify therapeutic targets for diseases such as breast cancer. The Human Breast Cell Atlas, published today in Nature, used single-cell and spatial genomic methods to profile more than 714,000 cells from 126 women. The breast atlas highlights 12 major cell types and 58 biological cell states, and identifies differences based on ethnicity, age and the menopause status of healthy women.
The University of Kansas Cancer Center has received a $100 million lead gift to build a new, state-of-the-art destination cancer center. This gift is both the largest gift ever given by the Sunderland Foundation and the largest ever received by the University of Kansas and The University of Kansas Health System.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting molecular targets and genomic events that trigger chromosomal instability and drive metastatic progression. The study, published today in Nature Cancer, demonstrates that the loss of a cluster of interferon receptor (IFNR) genes plays a pivotal role in allowing cancer cells to become tolerant of chromosomal instability. This genomic feature may be used to help clinicians predict a tumor’s potential to become metastatic and treatment resistant.
Cancer immunotherapy has revolutionized treatment of many forms of cancer by unleashing the immune system response against tumors. Immunotherapies that block checkpoint receptors like PD-1, proteins that limit the capacity of T cells to attack tumors, have become the choice for the treatment of numerous types of solid cancer.
MD Anderson and Ochsner Health announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Cancer patients in the region now have access to cancer treatments that are among the most advanced in the nation.
Researchers at the Ludwig Center at Harvard have developed a platform technology for imaging that enables integration of the methods of microscopic analysis long employed in pathology laboratories with the visualization of multiple molecular markers in individual cells that is now rapidly advancing in research labs.
The University of New Mexico Comprehensive Cancer Center is using the feedback it gets from young adult cancer survivors to craft a support group that fits their needs.
When Prajakta Adsul, MBBS, PhD, MPH, at the UNM Comprehensive Cancer Center, learned about LGBTQIA+ communities in New Mexico, she became inspired to start filling the void of information about cancer screening and survivorship in these populations. Using a novel survey, she and her team collected information from 2,500 individuals; it's the largest volume of data of its kind.
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a gene on the Y chromosome that is upregulated in KRAS-mutated colorectal cancer (CRC), increasing tumor cell invasiveness and reducing anti-tumor immunity in male patients.
Researchers at The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer.
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, were first presented at the European Society for Medical Oncology (ESMO) Congress 2022.
Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—convened a policy summit to examine how geography impacts cancer outcomes.
In a new paper, emergency medicine physician Samuel Clarke suggests the health education community re-design simulation-based teaching to utilize more adaptive expertise.
The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London.
Moffitt Cancer Center has launched the Department of Bioengineering. The new academic research department will be housed within the Division of Basic Science and led by W. Gregory Sawyer, Ph.D. Bioengineering integrates the disciplines of engineering and cancer biology.
New research in the June 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network found that when alectinib—a safe and effective small molecule kinase inhibitor used to treat some types of advanced lung cancer—was taken with a fuller breakfast, or with lunch, it resulted in significantly higher drug concentrations than when taken with a low-fat breakfast.
A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights into the evolution of multiple myeloma from precursor disease, which may help better identify patients likely to progress and develop new interventions
This case study by Dana-Farber gives evidence-based guidance for how to navigate decision-making for individual patients with metastatic hormone-sensitive prostate cancer.
A UC Davis MIND Institute researcher is testing a new framework aimed at helping more people with autism and intellectual disabilities find success with employment.
By their early 20s, two of Yale’s most prominent cancer experts had each been immersed in healthcare battles for many years. Few people would have been surprised if they chose careers outside of healthcare. Instead, Drs. Eric Winer and Patricia LoRusso chose to pursue cancer care and research as their work. Both are now leaders of two of the country’s most prestigious organizations for cancer professionals.
A new study led by Yale Cancer Center shows improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer taking osimertinib (TAGRISSO), a targeted therapy, following surgery. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, tends to recur when diagnosed at advanced stages, which makes treatment challenging.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
The Cancer Research Institute is honoring Dr. Tak Mak with the prestigious 2023 William B. Coley Award.
National Comprehensive Cancer Network’s Department of Policy and Advocacy calls on Federal Government, pharmaceutical industry, providers, and payers to work together on solutions, as 93% of cancer centers surveyed report a shortage of carboplatin and 70% report shortages for cisplatin; two medications that are used in combination to cure many types of cancer.
While the incidence of colorectal cancer (CRC) has dropped significantly among older adults in recent years — a trend attributed to regular screening colonoscopies and lower smoking rates — the opposite is true for people born between 1981 and 1996, who have double the risk compared with people born in 1950. There’s an urgent need to identify more-effective therapies for those younger people: Approximately 58% of patients age 50 or under have advanced, distant disease at the time of diagnosis, and only 14% of that group will survive five years.
An observational cohort study out of Roswell Park Comprehensive Cancer Center demonstrates that race and ethnicity affect a woman’s 21-gene recurrence score, a tool used to determine risk of recurrence and distant metastasis in patients with early-stage, hormone-receptor-positive breast cancer. Based on the expression of 21 cancer-related genes detected in pre-treatment tumor specimens, recurrence score is used routinely in clinical care to identify patients who might benefit from chemotherapy as part of their treatment plan. Scores range from 0-100, with a score of 26 or higher indicating greater risk of recurrence and poorer overall survival.
Research has shown that the immune system doesn’t function properly in patients with multiple myeloma, a blood cancer that occurs when plasma cells — a type of white blood cell — multiply out of control. But a clinical trial led by Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, shows that exercise may have the power to strengthen the immune system in those patients, providing a non-pharmaceutical method of helping control the disease.
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
Three clinical trials led by MD Anderson researchers showed positive results with the targeted therapy erdafitinib for patients with FGFR-altered tumors. The data were presented at the 2023 ASCO Annual Meeting.
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from an interim analysis of the Phase II DESTINY-PanTumor02 study, led by The University of Texas MD Anderson Cancer Center, were presented today at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
An MD Anderson-led Phase II trial showed the HER2-targeted therapy zanidatamab demonstrated durable responses in patients with advanced HER2-positive biliary tract cancer. The data were presented at the 2023 ASCO Annual Meeting.
Global celebration of 11 years of discovery and lifesaving innovation in immuno-oncology
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. If you’re covering the American Society for Clinical Oncology’s annual meeting, June 2-6 in Chicago, Illinois, see our list of Fred Hutch research highlights at ASCO and contact [email protected] to set up interviews with experts.
United States-based NCCN representatives visit Hanoi, Vietnam to work with local experts to improve quality-of-life for patients with cancer throughout the country.
Chimeric antigen receptor (CAR) T-cell therapy amplifies the immune system’s ability to recognize and kill cancer cells. The first CAR T-cell therapy was approved by the Food and Drug Administration (FDA) in 2017. Today, there are 6 FDA-approved CAR-based therapies to treat certain types of leukemia, lymphoma and myeloma, all of which are available at The University of Kansas Cancer Center.
During cancer treatment, everyone focuses on the part of the anatomy where the tumor is growing. A Penn State Cancer Institute oncologist talks about why you shouldn’t neglect everything else.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
